{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T20:51:29Z","timestamp":1790369489390,"version":"4.1.0"},"reference-count":103,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,8,18]],"date-time":"2022-08-18T00:00:00Z","timestamp":1660780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,8,18]],"date-time":"2022-08-18T00:00:00Z","timestamp":1660780800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has gained mutations at an alarming rate in the past years. Developing mutations can increase the virus's pathogenicity and virulence; reduce the efficacy of vaccines, antibodies neutralization, and even challenge adaptive immunity. So, it is essential to identify conserved epitopes (with fewer mutations) in different variants with appropriate antigenicity to target the variants by an appropriate vaccine design. Yet as, 3369 SARS-CoV-2 genomes were collected from global initiative on sharing avian flu data. Then, mutations in the immunodominant regions (IDRs), immune epitope database (IEDB) epitopes, and also predicted epitopes were calculated. In the following, epitopes conservity score against the total number of events (mutations) and the number of mutated sites in each epitope was weighted by Shannon entropy and then calculated by the Technique for Order of Preference by Similarity to Ideal Solution (TOPSIS). Based on the TOPSIS conservity score and antigenicity score, the epitopes were plotted. The result demonstrates that almost all epitopes and IDRs with various lengths have gained different numbers of mutations in dissimilar sites. Herein, our two-step calculation for conservity recommends only 8 IDRs, 14 IEDB epitopes, and 10 predicted epitopes among all epitopes. The selected ones have higher conservity and higher immunogenicity. This method is an open-source multi-criteria decision-making platform, which provides a scientific approach to selecting epitopes with appropriate conservity and immunogenicity; against ever-changing viruses.<\/jats:p>","DOI":"10.1038\/s41598-022-18152-5","type":"journal-article","created":{"date-parts":[[2022,8,18]],"date-time":"2022-08-18T10:03:22Z","timestamp":1660817002000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Considering epitopes conservity in targeting SARS-CoV-2 mutations in variants: a novel immunoinformatics approach to vaccine design"],"prefix":"10.1038","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7109-4476","authenticated-orcid":false,"given":"Mohammad Aref","family":"Bagherzadeh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Izadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazem","family":"Baesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirza Ali Mofazzal","family":"Jahromi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Majid","family":"Pirestani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,8,18]]},"reference":[{"key":"18152_CR1","unstructured":"Organization, W. H. in daily 1 (WHO, 2021)."},{"key":"18152_CR2","volume-title":"Origin of SARS-CoV-2","author":"WH Organization","year":"2020","unstructured":"Organization, W. H. Origin of SARS-CoV-2 (World Health Organization, 2020)."},{"key":"18152_CR3","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/j.jconrel.2021.06.036","volume":"336","author":"A Hasanzadeh","year":"2021","unstructured":"Hasanzadeh, A. et al. Nanotechnology against COVID-19: Immunization, diagnostic and therapeutic studies. J. Control Release 336, 354\u2013374. https:\/\/doi.org\/10.1016\/j.jconrel.2021.06.036 (2021).","journal-title":"J. Control Release"},{"key":"18152_CR4","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","volume":"395","author":"C Huang","year":"2020","unstructured":"Huang, C. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395, 497\u2013506 (2020).","journal-title":"Lancet"},{"key":"18152_CR5","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1038\/s41591-020-0820-9","volume":"26","author":"KG Andersen","year":"2020","unstructured":"Andersen, K. G., Rambaut, A., Lipkin, W. I., Holmes, E. C. & Garry, R. F. The proximal origin of SARS-CoV-2. Nat. Med. 26, 450\u2013452 (2020).","journal-title":"Nat. Med."},{"key":"18152_CR6","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1016\/S2213-2600(20)30226-5","volume":"8","author":"NE Ingraham","year":"2020","unstructured":"Ingraham, N. E. et al. Immunomodulation in COVID-19. Lancet Respir. Med. 8, 544\u2013546 (2020).","journal-title":"Lancet Respir. Med."},{"key":"18152_CR7","doi-asserted-by":"publisher","first-page":"e1008949","DOI":"10.1371\/journal.ppat.1008949","volume":"16","author":"H Zheng","year":"2020","unstructured":"Zheng, H. et al. Virulence and pathogenesis of SARS-CoV-2 infection in rhesus macaques: A nonhuman primate model of COVID-19 progression. PLoS Pathog. 16, e1008949 (2020).","journal-title":"PLoS Pathog."},{"key":"18152_CR8","doi-asserted-by":"publisher","first-page":"104371","DOI":"10.1016\/j.jcv.2020.104371","volume":"127","author":"Y Hu","year":"2020","unstructured":"Hu, Y. et al. Prevalence and severity of corona virus disease 2019 (COVID-19): A systematic review and meta-analysis. J. Clin. Virol. 127, 104371 (2020).","journal-title":"J. Clin. Virol."},{"key":"18152_CR9","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1080\/22221751.2020.1744483","volume":"9","author":"L Su","year":"2020","unstructured":"Su, L. et al. The different clinical characteristics of corona virus disease cases between children and their families in China\u2014The character of children with COVID-19. Emerg. Microbes Infect. 9, 707\u2013713 (2020).","journal-title":"Emerg. Microbes Infect."},{"key":"18152_CR10","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/S2468-1253(20)30132-1","volume":"5","author":"L Yang","year":"2020","unstructured":"Yang, L. & Tu, L. Implications of gastrointestinal manifestations of COVID-19. Lancet Gastroenterol. Hepatol. 5, 629\u2013630 (2020).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"18152_CR11","doi-asserted-by":"publisher","first-page":"116832","DOI":"10.1016\/j.jns.2020.116832","volume":"413","author":"AA Asadi-Pooya","year":"2020","unstructured":"Asadi-Pooya, A. A. & Simani, L. Central nervous system manifestations of COVID-19: A systematic review. J. Neurol. Sci. 413, 116832 (2020).","journal-title":"J. Neurol. Sci."},{"key":"18152_CR12","unstructured":"COVID-19 Vaccine Tracker and Landscape. https:\/\/www.who.int\/publications\/m\/item\/draft-landscape-of-covid-19-candidate-vaccines."},{"key":"18152_CR13","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/S0140-6736(20)31278-2","volume":"396","author":"Z Li","year":"2020","unstructured":"Li, Z. et al. Active case finding with case management: The key to tackling the COVID-19 pandemic. Lancet 396, 63\u201370 (2020).","journal-title":"Lancet"},{"key":"18152_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-021-21249-6","volume":"12","author":"L Di Domenico","year":"2021","unstructured":"Di Domenico, L., Pullano, G., Sabbatini, C. E., Bo\u00eblle, P.-Y. & Colizza, V. Modelling safe protocols for reopening schools during the COVID-19 pandemic in France. Nat. Commun. 12, 1\u201310 (2021).","journal-title":"Nat. Commun."},{"key":"18152_CR15","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1093\/infdis\/jiab295","volume":"224","author":"V De Giorgi","year":"2021","unstructured":"De Giorgi, V. et al. Naturally acquired SARS-CoV-2 immunity persists for up to 11 months following infection. J. Infect. Dis. 224, 1294\u20131304. https:\/\/doi.org\/10.1093\/infdis\/jiab295 (2021).","journal-title":"J. Infect. Dis."},{"key":"18152_CR16","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/S1473-3099(20)30926-9","volume":"21","author":"RH Dodd","year":"2021","unstructured":"Dodd, R. H. et al. Concerns and motivations about COVID-19 vaccination. Lancet Infect. Dis. 21, 161 (2021).","journal-title":"Lancet Infect. Dis."},{"key":"18152_CR17","unstructured":"Carl Zimmer, J. C. a. S.-L. W. (New York Times, 2021)."},{"key":"18152_CR18","first-page":"102","volume":"12","author":"H Allen","year":"2021","unstructured":"Allen, H. et al. Household transmission of COVID-19 cases associated with SARS-CoV-2 delta variant (B. 1.617. 2): National case-control study. Lancet Reg. Health-Eur. 12, 102 (2021).","journal-title":"Lancet Reg. Health-Eur."},{"key":"18152_CR19","doi-asserted-by":"publisher","first-page":"2372","DOI":"10.1016\/j.cell.2021.03.013","volume":"184","author":"WF Garcia-Beltran","year":"2021","unstructured":"Garcia-Beltran, W. F. et al. Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity. Cell 184, 2372\u20132383 (2021).","journal-title":"Cell"},{"key":"18152_CR20","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1038\/s41586-021-03361-1","volume":"592","author":"B Zhou","year":"2021","unstructured":"Zhou, B. et al. SARS-CoV-2 spike D614G change enhances replication and transmission. Nature 592, 122\u2013127 (2021).","journal-title":"Nature"},{"key":"18152_CR21","unstructured":"Prevention, C. F. D. C. A. SARS-CoV-2 Variant Classifications and Definitions\u2014CDC. https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/variants\/variant-classifications.html (2022)."},{"key":"18152_CR22","unstructured":"CDC. (The United States Centers for Disease Control and Prevention (CDC), 2021)."},{"key":"18152_CR23","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/j.chom.2021.04.007","volume":"29","author":"P Wang","year":"2021","unstructured":"Wang, P. et al. Increased resistance of SARS-CoV-2 variant P. 1 to antibody neutralization. Cell Host Microbe 29, 747\u2013751 (2021).","journal-title":"Cell Host Microbe"},{"key":"18152_CR24","doi-asserted-by":"publisher","first-page":"taab104","DOI":"10.1093\/jtm\/taab104","volume":"28","author":"PD Yadav","year":"2021","unstructured":"Yadav, P. D. et al. Neutralization of Beta and Delta variant with sera of COVID-19 recovered cases and vaccinees of inactivated COVID-19 vaccine BBV152\/Covaxin. J. Travel Med. 28, taab104 (2021).","journal-title":"J. Travel Med."},{"key":"18152_CR25","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1038\/s41586-021-03677-y","volume":"595","author":"EB Hodcroft","year":"2021","unstructured":"Hodcroft, E. B. et al. Spread of a SARS-CoV-2 variant through Europe in the summer of 2020. Nature 595, 707\u2013712 (2021).","journal-title":"Nature"},{"key":"18152_CR26","doi-asserted-by":"publisher","first-page":"104631","DOI":"10.1016\/j.compbiomed.2021.104631","volume":"136","author":"R Singh","year":"2021","unstructured":"Singh, R., Bhardwaj, V. K., Sharma, J., Kumar, D. & Purohit, R. Identification of potential plant bioactive as SARS-CoV-2 Spike protein and human ACE2 fusion inhibitors. Comput. Biol. Med. 136, 104631 (2021).","journal-title":"Comput. Biol. Med."},{"key":"18152_CR27","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.jtcme.2021.05.005","volume":"12","author":"R Singh","year":"2022","unstructured":"Singh, R., Bhardwaj, V. K., Sharma, J., Purohit, R. & Kumar, S. In-silico evaluation of bioactive compounds from tea as potential SARS-CoV-2 nonstructural protein 16 inhibitors. J. Tradit. Complement. Med. 12, 35\u201343 (2022).","journal-title":"J. Tradit. Complement. Med."},{"key":"18152_CR28","doi-asserted-by":"publisher","first-page":"3449","DOI":"10.1080\/07391102.2020.1766572","volume":"39","author":"VK Bhardwaj","year":"2021","unstructured":"Bhardwaj, V. K. et al. Identification of bioactive molecules from tea plant as SARS-CoV-2 main protease inhibitors. J. Biomol. Struct. Dyn. 39, 3449\u20133458 (2021).","journal-title":"J. Biomol. Struct. Dyn."},{"key":"18152_CR29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-020-79139-8","volume":"11","author":"Z Yang","year":"2021","unstructured":"Yang, Z., Bogdan, P. & Nazarian, S. An in silico deep learning approach to multi-epitope vaccine design: A SARS-CoV-2 case study. Sci. Rep. 11, 1\u201321 (2021).","journal-title":"Sci. Rep."},{"key":"18152_CR30","doi-asserted-by":"publisher","first-page":"e9572","DOI":"10.7717\/peerj.9572","volume":"8","author":"MS Rahman","year":"2020","unstructured":"Rahman, M. S. et al. Epitope-based chimeric peptide vaccine design against S, M and E proteins of SARS-CoV-2, the etiologic agent of COVID-19 pandemic: An in silico approach. PeerJ 8, e9572 (2020).","journal-title":"PeerJ"},{"key":"18152_CR31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41597-019-0340-y","volume":"7","author":"M Ostaszewski","year":"2020","unstructured":"Ostaszewski, M. et al. COVID-19 disease map, building a computational repository of SARS-CoV-2 virus-host interaction mechanisms. Sci. Data 7, 1\u20134 (2020).","journal-title":"Sci. Data"},{"key":"18152_CR32","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.micinf.2020.04.009","volume":"22","author":"MA Moreno-Eutimio","year":"2020","unstructured":"Moreno-Eutimio, M. A., Lopez-Macias, C. & Pastelin-Palacios, R. Bioinformatic analysis and identification of single-stranded RNA sequences recognized by TLR7\/8 in the SARS-CoV-2, SARS-CoV, and MERS-CoV genomes. Microbes Infect. 22, 226\u2013229 (2020).","journal-title":"Microbes Infect."},{"key":"18152_CR33","doi-asserted-by":"publisher","first-page":"104555","DOI":"10.1016\/j.compbiomed.2021.104555","volume":"135","author":"R Singh","year":"2021","unstructured":"Singh, R., Bhardwaj, V. K., Das, P. & Purohit, R. A computational approach for rational discovery of inhibitors for non-structural protein 1 of SARS-CoV-2. Comput. Biol. Med. 135, 104555 (2021).","journal-title":"Comput. Biol. Med."},{"key":"18152_CR34","doi-asserted-by":"publisher","first-page":"128933","DOI":"10.1016\/j.foodchem.2020.128933","volume":"346","author":"J Sharma","year":"2021","unstructured":"Sharma, J. et al. An in-silico evaluation of different bioactive molecules of tea for their inhibition potency against non structural protein-15 of SARS-CoV-2. Food Chem. 346, 128933 (2021).","journal-title":"Food Chem."},{"key":"18152_CR35","doi-asserted-by":"publisher","first-page":"104965","DOI":"10.1016\/j.compbiomed.2021.104965","volume":"139","author":"R Singh","year":"2021","unstructured":"Singh, R., Bhardwaj, V. K. & Purohit, R. Potential of turmeric-derived compounds against RNA-dependent RNA polymerase of SARS-CoV-2: An in-silico approach. Comput. Biol. Med. 139, 104965 (2021).","journal-title":"Comput. Biol. Med."},{"key":"18152_CR36","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.684020","author":"VK Bhardwaj","year":"2021","unstructured":"Bhardwaj, V. K. et al. Bioactive molecules of Tea as potential inhibitors for RNA-dependent RNA polymerase of SARS-CoV-2. Front. Med. https:\/\/doi.org\/10.3389\/fmed.2021.684020 (2021).","journal-title":"Front. Med."},{"key":"18152_CR37","doi-asserted-by":"publisher","first-page":"e0244176","DOI":"10.1371\/journal.pone.0244176","volume":"15","author":"M Tahir ul Qamar","year":"2020","unstructured":"Tahir ul Qamar, M. et al. Designing of a next generation multiepitope based vaccine (MEV) against SARS-COV-2: Immunoinformatics and in silico approaches. PLoS ONE 15, e0244176 (2020).","journal-title":"PLoS ONE"},{"key":"18152_CR38","doi-asserted-by":"publisher","first-page":"3793","DOI":"10.1080\/07391102.2020.1770127","volume":"39","author":"K Abraham Peele","year":"2021","unstructured":"Abraham Peele, K., Srihansa, T., Krupanidhi, S., Ayyagari, V. S. & Venkateswarulu, T. Design of multi-epitope vaccine candidate against SARS-CoV-2: A in-silico study. J. Biomol. Struct. Dyn. 39, 3793\u20133801 (2021).","journal-title":"J. Biomol. Struct. Dyn."},{"key":"18152_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s42003-021-02095-0","volume":"4","author":"MG Ferrarini","year":"2021","unstructured":"Ferrarini, M. G. et al. Genome-wide bioinformatic analyses predict key host and viral factors in SARS-CoV-2 pathogenesis. Commun. Biol. 4, 1\u201315 (2021).","journal-title":"Commun. Biol."},{"key":"18152_CR40","doi-asserted-by":"publisher","first-page":"e1003266","DOI":"10.1371\/journal.pcbi.1003266","volume":"9","author":"JJ Calis","year":"2013","unstructured":"Calis, J. J. et al. Properties of MHC class I presented peptides that enhance immunogenicity. PLoS Comput. Biol. 9, e1003266. https:\/\/doi.org\/10.1371\/journal.pcbi.1003266 (2013).","journal-title":"PLoS Comput. Biol."},{"key":"18152_CR41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2105-11-568","volume":"11","author":"P Wang","year":"2010","unstructured":"Wang, P. et al. Peptide binding predictions for HLA DR, DP and DQ molecules. BMC Bioinform. 11, 1\u201312 (2010).","journal-title":"BMC Bioinform."},{"key":"18152_CR42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1745-7580-4-2","volume":"4","author":"J Sidney","year":"2008","unstructured":"Sidney, J. et al. Quantitative peptide binding motifs for 19 human and mouse MHC class I molecules derived using positional scanning combinatorial peptide libraries. Immunome Res. 4, 1\u201314 (2008).","journal-title":"Immunome Res."},{"key":"18152_CR43","doi-asserted-by":"publisher","first-page":"eabg3055","DOI":"10.1126\/science.abg3055","volume":"372","author":"NG Davies","year":"2021","unstructured":"Davies, N. G. et al. Estimated transmissibility and impact of SARS-CoV-2 lineage B. 1.1. 7 in England. Science 372, eabg3055 (2021).","journal-title":"Science"},{"key":"18152_CR44","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1016\/j.cell.2020.07.012","volume":"182","author":"Q Li","year":"2020","unstructured":"Li, Q. et al. The impact of mutations in SARS-CoV-2 spike on viral infectivity and antigenicity. Cell 182, 1284\u20131294 (2020).","journal-title":"Cell"},{"key":"18152_CR45","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1038\/s41586-021-03398-2","volume":"593","author":"P Wang","year":"2021","unstructured":"Wang, P. et al. Antibody resistance of SARS-CoV-2 variants B. 1.351 and B. 1.1. 7. Nature 593, 130\u2013135 (2021).","journal-title":"Nature"},{"key":"18152_CR46","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.chom.2020.11.012","volume":"29","author":"D Weissman","year":"2021","unstructured":"Weissman, D. et al. D614G spike mutation increases SARS CoV-2 susceptibility to neutralization. Cell Host Microbe 29, 23\u201331 (2021).","journal-title":"Cell Host Microbe"},{"key":"18152_CR47","doi-asserted-by":"publisher","first-page":"e283","DOI":"10.1016\/S2666-5247(21)00068-9","volume":"2","author":"S Jangra","year":"2021","unstructured":"Jangra, S. et al. SARS-CoV-2 spike E484K mutation reduces antibody neutralisation. Lancet Microbe 2, e283\u2013e284 (2021).","journal-title":"Lancet Microbe"},{"key":"18152_CR48","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1146\/annurev.micro.51.1.151","volume":"51","author":"E Domingo","year":"1997","unstructured":"Domingo, E. & Holland, J. RNA virus mutations and fitness for survival. Ann. Rev. Microbiol. 51, 151\u2013178 (1997).","journal-title":"Ann. Rev. Microbiol."},{"key":"18152_CR49","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-017-02816-2","volume":"9","author":"H Xia","year":"2018","unstructured":"Xia, H. et al. An evolutionary NS1 mutation enhances Zika virus evasion of host interferon induction. Nat. Commun. 9, 1\u201313 (2018).","journal-title":"Nat. Commun."},{"key":"18152_CR50","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1038\/d41586-020-02544-6","volume":"585","author":"E Callaway","year":"2020","unstructured":"Callaway, E. Making sense of coronavirus mutations. Nature 585, 174\u2013177 (2020).","journal-title":"Nature"},{"key":"18152_CR51","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1016\/S0140-6736(19)32682-0","volume":"395","author":"L-G Bekker","year":"2020","unstructured":"Bekker, L.-G. et al. The complex challenges of HIV vaccine development require renewed and expanded global commitment. Lancet 395, 384\u2013388 (2020).","journal-title":"Lancet"},{"key":"18152_CR52","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1038\/ni0304-233","volume":"5","author":"DR Burton","year":"2004","unstructured":"Burton, D. R. et al. HIV vaccine design and the neutralizing antibody problem. Nat. Immunol. 5, 233\u2013236 (2004).","journal-title":"Nat. Immunol."},{"key":"18152_CR53","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/s41586-020-2008-3","volume":"579","author":"F Wu","year":"2020","unstructured":"Wu, F. et al. A new coronavirus associated with human respiratory disease in China. Nature 579, 265\u2013269 (2020).","journal-title":"Nature"},{"key":"18152_CR54","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1016\/j.cell.2020.04.026","volume":"181","author":"D Blanco-Melo","year":"2020","unstructured":"Blanco-Melo, D. et al. Imbalanced host response to SARS-CoV-2 drives development of COVID-19. Cell 181, 1036\u20131045 (2020).","journal-title":"Cell"},{"key":"18152_CR55","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1126\/science.abb7498","volume":"368","author":"Y Gao","year":"2020","unstructured":"Gao, Y. et al. Structure of the RNA-dependent RNA polymerase from COVID-19 virus. Science 368, 779\u2013782 (2020).","journal-title":"Science"},{"key":"18152_CR56","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1093\/sysbio\/syw037","volume":"65","author":"O Chernomor","year":"2016","unstructured":"Chernomor, O., von Haeseler, A. & Minh, B. Q. Terrace aware data structure for phylogenomic inference from supermatrices. Syst. Biol. 65, 997\u20131008. https:\/\/doi.org\/10.1093\/sysbio\/syw037 (2016).","journal-title":"Syst. Biol."},{"key":"18152_CR57","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1111\/imm.12984","volume":"155","author":"SK Dhanda","year":"2018","unstructured":"Dhanda, S. K. et al. Development of a novel clustering tool for linear peptide sequences. Immunology 155, 331\u2013345 (2018).","journal-title":"Immunology"},{"key":"18152_CR58","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1111\/imm.12816","volume":"153","author":"SK Dhanda","year":"2018","unstructured":"Dhanda, S. K. et al. Development of a strategy and computational application to select candidate protein analogues with reduced HLA binding and immunogenicity. Immunology 153, 118\u2013132 (2018).","journal-title":"Immunology"},{"key":"18152_CR59","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1080\/22221751.2021.2022440","volume":"11","author":"J Ai","year":"2022","unstructured":"Ai, J. et al. Omicron variant showed lower neutralizing sensitivity than other SARS-CoV-2 variants to immune sera elicited by vaccines after boost. Emerg. Microbes Infect. 11, 337\u2013343 (2022).","journal-title":"Emerg. Microbes Infect."},{"key":"18152_CR60","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1371\/journal.ppat.1010022","volume":"17","author":"C Davis","year":"2021","unstructured":"Davis, C. et al. Reduced neutralisation of the Delta (B. 1.617. 2) SARS-CoV-2 variant of concern following vaccination. PLoS Pathog. 17, 22 (2021).","journal-title":"PLoS Pathog."},{"key":"18152_CR61","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/S0140-6736(21)02844-0","volume":"399","author":"W Dejnirattisai","year":"2022","unstructured":"Dejnirattisai, W. et al. Reduced neutralisation of SARS-CoV-2 omicron B. 1.1. 529 variant by post-immunisation serum. Lancet 399, 234\u2013236 (2022).","journal-title":"Lancet"},{"key":"18152_CR62","doi-asserted-by":"publisher","DOI":"10.1101\/2021.12.07.21267432","author":"A Wilhelm","year":"2021","unstructured":"Wilhelm, A. et al. Reduced neutralization of SARS-CoV-2 Omicron variant by vaccine sera and monoclonal antibodies. MedRxiv https:\/\/doi.org\/10.1101\/2021.12.07.21267432 (2021).","journal-title":"MedRxiv"},{"key":"18152_CR63","doi-asserted-by":"publisher","DOI":"10.1101\/2021.12.15.472828","author":"LA VanBlargan","year":"2021","unstructured":"VanBlargan, L. A. et al. An infectious SARS-CoV-2 B. 1.1. 529 Omicron virus escapes neutralization by several therapeutic monoclonal antibodies. BioRxiv https:\/\/doi.org\/10.1101\/2021.12.15.472828 (2021).","journal-title":"BioRxiv"},{"key":"18152_CR64","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1038\/s41591-021-01678-y","volume":"28","author":"LA VanBlargan","year":"2022","unstructured":"VanBlargan, L. A. et al. An infectious SARS-CoV-2 B. 1.1. 529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies. Nat. Med. 28, 490\u2013495 (2022).","journal-title":"Nat. Med."},{"key":"18152_CR65","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1016\/0305-0548(93)90109-V","volume":"20","author":"C-L Hwang","year":"1993","unstructured":"Hwang, C.-L., Lai, Y.-J. & Liu, T.-Y. A new approach for multiple objective decision making. Comput. Oper. Res. 20, 889\u2013899. https:\/\/doi.org\/10.1016\/0305-0548(93)90109-V (1993).","journal-title":"Comput. Oper. Res."},{"key":"18152_CR66","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/1471-2105-8-4","volume":"8","author":"IA Doytchinova","year":"2007","unstructured":"Doytchinova, I. A. & Flower, D. R. VaxiJen: A server for prediction of protective antigens, tumour antigens and subunit vaccines. BMC Bioinform. 8, 4. https:\/\/doi.org\/10.1186\/1471-2105-8-4 (2007).","journal-title":"BMC Bioinform."},{"key":"18152_CR67","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1016\/j.vaccine.2006.09.032","volume":"25","author":"IA Doytchinova","year":"2007","unstructured":"Doytchinova, I. A. & Flower, D. R. Identifying candidate subunit vaccines using an alignment-independent method based on principal amino acid properties. Vaccine 25, 856\u2013866 (2007).","journal-title":"Vaccine"},{"key":"18152_CR68","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.jim.2015.03.022","volume":"422","author":"S Paul","year":"2015","unstructured":"Paul, S. et al. Development and validation of a broad scheme for prediction of HLA class II restricted T cell epitopes. J. Immunol. Methods 422, 28\u201334 (2015).","journal-title":"J. Immunol. Methods"},{"key":"18152_CR69","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1002\/cpim.12","volume":"114","author":"S Paul","year":"2016","unstructured":"Paul, S., Sidney, J., Sette, A. & Peters, B. TepiTool: A pipeline for computational prediction of T cell epitope candidates. Curr. Protoc. Immunol. 114, 18\u201319 (2016).","journal-title":"Curr. Protoc. Immunol."},{"key":"18152_CR70","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00894-014-2278-5","volume":"20","author":"I Dimitrov","year":"2014","unstructured":"Dimitrov, I., Bangov, I., Flower, D. R. & Doytchinova, I. AllerTOP v. 2\u2014A server for in silico prediction of allergens. J. Mol. Model. 20, 1\u20136 (2014).","journal-title":"J. Mol. Model."},{"key":"18152_CR71","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1186\/1471-2105-8-424","volume":"8","author":"MV Larsen","year":"2007","unstructured":"Larsen, M. V. et al. Large-scale validation of methods for cytotoxic T-lymphocyte epitope prediction. BMC Bioinform. 8, 424. https:\/\/doi.org\/10.1186\/1471-2105-8-424 (2007).","journal-title":"BMC Bioinform."},{"key":"18152_CR72","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2105-8-424","volume":"8","author":"MV Larsen","year":"2007","unstructured":"Larsen, M. V. et al. Large-scale validation of methods for cytotoxic T-lymphocyte epitope prediction. BMC Bioinform. 8, 1\u201312 (2007).","journal-title":"BMC Bioinform."},{"key":"18152_CR73","unstructured":"IFNepitope. https:\/\/webs.iiitd.edu.in\/raghava\/ifnepitope\/index.php."},{"key":"18152_CR74","unstructured":"IL4pred. https:\/\/webs.iiitd.edu.in\/raghava\/il4pred\/design.php."},{"key":"18152_CR75","unstructured":"IL-10Pred. https:\/\/webs.iiitd.edu.in\/raghava\/il10pred\/index.html."},{"key":"18152_CR76","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01695","author":"B Manavalan","year":"2018","unstructured":"Manavalan, B., Govindaraj, R. G., Shin, T. H., Kim, M. O. & Lee, G. iBCE-EL: A new ensemble learning framework for improved linear B-cell epitope prediction. Front. Immunol. https:\/\/doi.org\/10.3389\/fimmu.2018.01695 (2018).","journal-title":"Front. Immunol."},{"key":"18152_CR77","doi-asserted-by":"publisher","first-page":"101064","DOI":"10.1016\/j.genrep.2021.101064","volume":"23","author":"Z Almubaid","year":"2021","unstructured":"Almubaid, Z. & Al-Mubaid, H. Analysis and comparison of genetic variants and mutations of the novel coronavirus SARS-CoV-2. Gene Rep. 23, 101064 (2021).","journal-title":"Gene Rep."},{"key":"18152_CR78","doi-asserted-by":"publisher","first-page":"3226","DOI":"10.1016\/j.ygeno.2020.06.016","volume":"112","author":"SS Hassan","year":"2020","unstructured":"Hassan, S. S., Choudhury, P. P., Basu, P. & Jana, S. S. Molecular conservation and differential mutation on ORF3a gene in Indian SARS-CoV2 genomes. Genomics 112, 3226\u20133237 (2020).","journal-title":"Genomics"},{"key":"18152_CR79","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.ijbiomac.2021.11.151","volume":"194","author":"SS Hassan","year":"2022","unstructured":"Hassan, S. S. et al. Emergence of unique SARS-CoV-2 ORF10 variants and their impact on protein structure and function. Int. J. Biol. Macromol. 194, 128\u2013143 (2022).","journal-title":"Int. J. Biol. Macromol."},{"key":"18152_CR80","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-020-72533-2","volume":"10","author":"J Kames","year":"2020","unstructured":"Kames, J. et al. Sequence analysis of SARS-CoV-2 genome reveals features important for vaccine design. Sci. Rep. 10, 1\u201311 (2020).","journal-title":"Sci. Rep."},{"key":"18152_CR81","doi-asserted-by":"publisher","first-page":"e0249254","DOI":"10.1371\/journal.pone.0249254","volume":"16","author":"B Schr\u00f6rs","year":"2021","unstructured":"Schr\u00f6rs, B. et al. Large-scale analysis of SARS-CoV-2 spike-glycoprotein mutants demonstrates the need for continuous screening of virus isolates. PLoS ONE 16, e0249254 (2021).","journal-title":"PLoS ONE"},{"key":"18152_CR82","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1080\/20477724.2020.1838190","volume":"114","author":"Y Dai","year":"2020","unstructured":"Dai, Y. et al. Immunodominant regions prediction of nucleocapsid protein for SARS-CoV-2 early diagnosis: A bioinformatics and immunoinformatics study. Pathog. Glob. Health 114, 463\u2013470 (2020).","journal-title":"Pathog. Glob. Health"},{"key":"18152_CR83","doi-asserted-by":"publisher","first-page":"e11232","DOI":"10.7717\/peerj.11232","volume":"9","author":"S Zhuang","year":"2021","unstructured":"Zhuang, S. et al. Bioinformatic prediction of immunodominant regions in spike protein for early diagnosis of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). PeerJ 9, e11232 (2021).","journal-title":"PeerJ"},{"key":"18152_CR84","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12038-020-00046-1","volume":"45","author":"A Maitra","year":"2020","unstructured":"Maitra, A. et al. Mutations in SARS-CoV-2 viral RNA identified in Eastern India: Possible implications for the ongoing outbreak in India and impact on viral structure and host susceptibility. J. Biosci. 45, 1\u201318 (2020).","journal-title":"J. Biosci."},{"key":"18152_CR85","doi-asserted-by":"publisher","first-page":"101606","DOI":"10.1016\/j.bjid.2021.101606","volume":"25","author":"M Mohammadi","year":"2021","unstructured":"Mohammadi, M., Shayestehpour, M. & Mirzaei, H. The impact of spike mutated variants of SARS-CoV2 [Alpha, Beta, Gamma, Delta, and Lambda] on the efficacy of subunit recombinant vaccines. Braz. J. Infect. Dis. 25, 101606 (2021).","journal-title":"Braz. J. Infect. Dis."},{"key":"18152_CR86","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1038\/s41579-021-00573-0","volume":"19","author":"WT Harvey","year":"2021","unstructured":"Harvey, W. T. et al. SARS-CoV-2 variants, spike mutations and immune escape. Nat. Rev. Microbiol. 19, 409\u2013424 (2021).","journal-title":"Nat. Rev. Microbiol."},{"key":"18152_CR87","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.chom.2021.02.003","volume":"29","author":"AJ Greaney","year":"2021","unstructured":"Greaney, A. J. et al. Comprehensive mapping of mutations in the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human plasma antibodies. Cell Host Microbe 29, 463\u2013476 (2021).","journal-title":"Cell Host Microbe"},{"key":"18152_CR88","doi-asserted-by":"publisher","DOI":"10.1101\/2020.03.27.012013","author":"E Issa","year":"2020","unstructured":"Issa, E., Merhi, G., Panossian, B., Salloum, T. & Tokajian, S. SARS-CoV-2 and ORF3a: Non-synonymous mutations and polyproline regions. bioRxiv https:\/\/doi.org\/10.1101\/2020.03.27.012013 (2020).","journal-title":"bioRxiv"},{"key":"18152_CR89","doi-asserted-by":"publisher","first-page":"111599","DOI":"10.1016\/j.biopha.2021.111599","volume":"139","author":"E Mohammadi","year":"2021","unstructured":"Mohammadi, E. et al. Novel and emerging mutations of SARS-CoV-2: Biomedical implications. Biomed. Pharmacother. 139, 111599 (2021).","journal-title":"Biomed. Pharmacother."},{"key":"18152_CR90","doi-asserted-by":"publisher","first-page":"104915","DOI":"10.1016\/j.compbiomed.2021.104915","volume":"138","author":"B Mullick","year":"2021","unstructured":"Mullick, B., Magar, R., Jhunjhunwala, A. & Farimani, A. B. Understanding mutation hotspots for the sars-cov-2 spike protein using shannon entropy and k-means clustering. Comput. Biol. Med. 138, 104915 (2021).","journal-title":"Comput. Biol. Med."},{"key":"18152_CR91","doi-asserted-by":"publisher","first-page":"2927","DOI":"10.1016\/j.cell.2021.04.045","volume":"184","author":"ME Garrett","year":"2021","unstructured":"Garrett, M. E. et al. High-resolution profiling of pathways of escape for SARS-CoV-2 spike-binding antibodies. Cell 184, 2927\u20132938 (2021).","journal-title":"Cell"},{"key":"18152_CR92","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1016\/j.ijbiomac.2020.06.213","volume":"162","author":"I Ahammad","year":"2020","unstructured":"Ahammad, I. & Lira, S. S. Designing a novel mRNA vaccine against SARS-CoV-2: An immunoinformatics approach. Int. J. Biol. Macromol. 162, 820\u2013837 (2020).","journal-title":"Int. J. Biol. Macromol."},{"key":"18152_CR93","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1002\/j.1460-2075.1991.tb08022.x","volume":"10","author":"JG Cyster","year":"1991","unstructured":"Cyster, J. G., Shotton, D. M. & Williams, A. F. The dimensions of the T lymphocyte glycoprotein leukosialin and identification of linear protein epitopes that can be modified by glycosylation. EMBO J. 10, 893\u2013902 (1991).","journal-title":"EMBO J."},{"key":"18152_CR94","doi-asserted-by":"publisher","first-page":"W24","DOI":"10.1093\/nar\/gkx346","volume":"45","author":"MC Jespersen","year":"2017","unstructured":"Jespersen, M. C., Peters, B., Nielsen, M. & Marcatili, P. BepiPred-2.0: Improving sequence-based B-cell epitope prediction using conformational epitopes. Nucleic Acids Res. 45, W24\u2013W29 (2017).","journal-title":"Nucleic Acids Res."},{"key":"18152_CR95","doi-asserted-by":"publisher","first-page":"3509","DOI":"10.1016\/j.vaccine.2014.04.039","volume":"32","author":"NJ Steers","year":"2014","unstructured":"Steers, N. J. et al. Designing the epitope flanking regions for optimal generation of CTL epitopes. Vaccine 32, 3509\u20133516 (2014).","journal-title":"Vaccine"},{"key":"18152_CR96","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.3389\/fimmu.2020.01784","volume":"11","author":"R Dong","year":"2020","unstructured":"Dong, R., Chu, Z., Yu, F. & Zha, Y. Contriving multi-epitope subunit of vaccine for COVID-19: Immunoinformatics approaches. Front. Immunol. 11, 1784 (2020).","journal-title":"Front. Immunol."},{"key":"18152_CR97","doi-asserted-by":"publisher","first-page":"104236","DOI":"10.1016\/j.micpath.2020.104236","volume":"145","author":"P Kalita","year":"2020","unstructured":"Kalita, P., Padhi, A. K., Zhang, K. Y. & Tripathi, T. Design of a peptide-based subunit vaccine against novel coronavirus SARS-CoV-2. Microb. Pathog. 145, 104236 (2020).","journal-title":"Microb. Pathog."},{"key":"18152_CR98","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/j.chom.2020.03.002","volume":"27","author":"A Grifoni","year":"2020","unstructured":"Grifoni, A. et al. A sequence homology and bioinformatic approach can predict candidate targets for immune responses to SARS-CoV-2. Cell Host Microbe 27, 671\u2013680 (2020).","journal-title":"Cell Host Microbe"},{"key":"18152_CR99","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1186\/1471-2105-11-568","volume":"11","author":"P Wang","year":"2010","unstructured":"Wang, P. et al. Peptide binding predictions for HLA DR, DP and DQ molecules. BMC Bioinform. 11, 568. https:\/\/doi.org\/10.1186\/1471-2105-11-568 (2010).","journal-title":"BMC Bioinform."},{"key":"18152_CR100","doi-asserted-by":"publisher","first-page":"W449","DOI":"10.1093\/nar\/gkaa379","volume":"48","author":"B Reynisson","year":"2020","unstructured":"Reynisson, B., Alvarez, B., Paul, S., Peters, B. & Nielsen, M. NetMHCpan-4.1 and NetMHCIIpan-4.0: Improved predictions of MHC antigen presentation by concurrent motif deconvolution and integration of MS MHC eluted ligand data. Nucleic Acids Res. 48, W449\u2013W454. https:\/\/doi.org\/10.1093\/nar\/gkaa379 (2020).","journal-title":"Nucleic Acids Res."},{"key":"18152_CR101","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.3389\/fimmu.2018.01695","volume":"9","author":"B Manavalan","year":"2018","unstructured":"Manavalan, B., Govindaraj, R. G., Shin, T. H., Kim, M. O. & Lee, G. iBCE-EL: A new ensemble learning framework for improved linear B-cell epitope prediction. Front. Immunol. 9, 1695 (2018).","journal-title":"Front. Immunol."},{"key":"18152_CR102","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/978-1-4939-2285-7_7","volume":"1268","author":"S Gupta","year":"2015","unstructured":"Gupta, S. et al. Peptide toxicity prediction. Methods Mol. Biol. (Clifton, N.J.) 1268, 143\u2013157. https:\/\/doi.org\/10.1007\/978-1-4939-2285-7_7 (2015).","journal-title":"Methods Mol. Biol. (Clifton, N.J.)"},{"key":"18152_CR103","doi-asserted-by":"publisher","first-page":"e73957","DOI":"10.1371\/journal.pone.0073957","volume":"8","author":"S Gupta","year":"2013","unstructured":"Gupta, S. et al. In silico approach for predicting toxicity of peptides and proteins. PLoS ONE 8, e73957 (2013).","journal-title":"PLoS ONE"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-18152-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-18152-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-18152-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,25]],"date-time":"2022-11-25T06:54:54Z","timestamp":1669359294000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-18152-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,18]]},"references-count":103,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["18152"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-18152-5","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,18]]},"assertion":[{"value":"10 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"14017"}}